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Background: Avascular necrosis (AVN) of the femoral head (FH) is believed to be caused by a multitude of
etiologic factors and is associated with significant morbidity in younger populations. Eventually, the disease
progresses and results in FH collapse. Thus, a focus on early disease management aimed at joint preservation by
preventing or delaying progression is key. The use of stem cells (SC) for the treatment of AVN of the FH has been
proposed. We undertook a systematic review of the medical literature examining the use of SC for the treatment of
early stage (precollapse) AVN of the FH, in both pre-clinical and clinical studies.
Methods: Data collected included: Pre-clinical studies – model of AVN, variety and dosage of SC, histologic and
imaging analyses. Clinical studies – study design, classification and etiology of AVN, SC dosage and treatment protocol,
incidence of disease progression, patient reported outcomes, volume of necrotic lesion and hip survivorship.
Results: In pre-clinical studies, the use of SC uniformly demonstrated improvements in osteogenesis and
angiogenesis, yet source of implanted SC was variable. In clinical studies, groups treated with SC showed
significant improvements in patient reported outcomes; however hip survivorship was not affected. Discrepancies
regarding dose of SC, AVN etiology and disease severity were present.
Conclusions: Routine use of this treatment method will first require further research into dose and quality
optimization as well as confirmed improvements in hip survivorship.
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Avascular necrosis (AVN) of the femoral head (FH) is a
debilitating and painful disease with multiple etiologic
risk factors [1-4]. These include, but are not limited to,
corticosteroid use [1,3-6], alcohol abuse [1-4], previous
trauma [1,3], hemoglobinopathy [7], Gaucher’s disease
and coagulopathies [8]. The onset of AVN may also be
idiopathic [7]. AVN of the FH most commonly affects
younger or middle aged adults [2,9,10]. Disease progres-
sion commonly leads to collapse of the affected FH and
ultimately, development of osteoarthritis [1,3,4,7,11,12].
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unless otherwise stated.patients have been poor, primarily due to the limited
lifetime and durability of total hip arthroplasty (THA)
[6,10,11]. As a result, there has been an increased focus
on early-interventions for AVN, aimed at preservation of
the native articulation [6,12]. Core decompression (CD)
is currently the most widely accepted treatment for early-
stage AVN of the FH; however, due to limited efficacy, its
use has been debated [12]. The development of safe, cost-
effective, and potentially minimally invasive joint preserv-
ing treatments for early stage (precollapse) AVN merits
further investigation.
Several studies, both clinical and pre-clinical, have dem-
onstrated the efficacy of stem cells (SC) for the treatment
of AVN of the FH [1,3,11,13-15]. SC can be obtained from
a variety of sources, including autologous bone marrow
[2,4,10,11,16,17], adipose tissue [10] and dental-pulp [4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4,6,11,12] and neovascularization [6,11] in vitro. Add-
itionally, patients treated with SC in conjunction with
CD demonstrated significant improvements in Harris
Hip Scores (HHS) [15] as well as decreased hip pain
and symptoms compared to those treated with CD
alone [2]. Yan et al. documented that stem cells im-
planted into the necrotic FH not only survive, but thrive
and proliferate [15]. Although the pathogenesis of AVN
is unclear [17] many hypothesize that SC work to im-
prove early stage AVN potentially as a function of their
critical role in the regulation and improvement of
osteogenesis and angiogenesis [11,12]. Furthermore, it
is thought that mesenchymal SC implanted into the
necrotic FH may differentiate into osteoblasts or vascu-
lar endothelial cells, thereby promoting bone repair and
regeneration [12]. Despite encouraging results in pre-
clinical (basic science) and clinical studies, improve-
ments in hip survivorship or time to THA has not been
uniformly reported and remains controversial [2,8,14].
The purpose of our study was to perform a systematic
review of the current medical literature on the treatment
of early stage AVN of the FH using SC implanted via
CD. We examined both preclinical studies and clinical
studies. We reported bone healing outcomes (histologic
and imaging outcomes) from preclinical papers and all
examined outcomes from available clinical papers.
Methods
Eligibility criteria
Manuscripts were deemed eligible for our review if they
evaluated treatment of early stage AVN of the FH with
SC implanted via CD. We defined early stage AVN as
precollapse of the FH. Both clinical and preclinical manu-
scripts were selected. For clinical trials, we included stud-
ies on patients age > 18. All types of clinical studies were
eligible for inclusion to this review. Studies of all languages
were eligible for inclusion to this review. For studies
reporting on the same group of patients at multiple follow
up periods, the most recent publication was used in this
review. For preclinical studies, manuscripts were eligible if
they examined bone healing either histologically, or by im-
aging techniques. If studies examined other treatments
such as vascularized fibular grafting or bone morphogenic
proteins, they were excluded unless the data on SC and
CD were presented separately from the other treatments,
to allow us to examine the effect of SC specifically.
Study identification
A systematic, computerized search for potential manu-
scripts was performed by three independent reviewers
(HE, SM, RL). Pubmed (−July 2012), Ovid Medline (−July
2012) and EMBASE (−July 2012) databases were used to
identify studies. Key words used for the search were: AVNor avascular necrosis or osteonecrosis AND stem cells;
AVN or avascular necrosis or osteonecrosis AND au-
tologous bone marrow. Abstracts were retrieved for all
manuscripts considered relevant by title. Abstracts were
independently reviewed and any disagreements were
resolved by discussion. Full length articles of relevant
abstracts were reviewed for inclusion. Bibliographies of
the full length articles were also searched for other po-
tential studies and full length articles were retrieved.
Outcomes data were extracted by two reviewers (HE,
RL) using prearranged summary tables. Data extraction
for preclinical studies included study design, animal
model, type of SC used, sample size, and outcomes mea-
sured. For the clinical studies, study type, sample size, po-
tential biases, AVN classification, AVN etiology, SC dose
and cell type, and outcomes measured were recorded.
Results
Study selection
We identified 215 abstracts using our electronic search.
Thirty-four met the initial screening inclusion criteria
and the full-length articles were retrieved and reviewed.
Following the full-length reviews, 16 studies (11 pre-
clinical, 5 clinical) met our inclusion criteria and were
retained for this review. Eighteen studies were excluded: 3
were review articles [18-20], one was a surgical technique
article [21], 3 articles were early/pilot results which were
subsequently included in future articles [7,16,22], 6 articles
examined SC treatment in conjunction with therapies
other than CD (i.e. vascularized fibula) [23-28], two arti-
cles used SC transplanted intravenously instead of by
CD [13,29], 1 article examined prevention of AVN not
treatment [5], and two articles included patients with
post collapse AVN of the FH [1,15] (Figure 1).
Preclinical study characteristics
Study design
All preclinical studies utilized an animal model (8 rabbit
[6,10,17,30-34], 2 dog [11,12] and 1 sheep model [4]).
AVN was induced using methylprednisolone injection in
6 of the 11 studies [6,10,30-32,34]. One model utilized
liquid nitrogen to create AVN of the FH [17]. Three
studies utilized a femoral neck osteotomy to induce AVN
[11,12,33]. One study induced AVN by instillation of
ethanol to the FH via CD [4].
Stem cell treatment
The type of SC implanted were variable yet may be clas-
sified into three groups: 1) bone marrow derived stem
cells – concentrated, un-cultured bone marrow mono-
nuclear cells (BMMNC), fresh (1 study) [6] or cryopre-
served (1 study) [32], and mesenchymal stem cells
obtained post BMMNC culture (4 studies) [11,12,30,33];
2) adipose derived stem cells (2 studies) [10,34]; 3) other –
Figure 1 Search, screening and selection of articles for review.
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endothelial progenitor cells (EPC) (1 study) [31], and
human immature dental pulp SC (1 study) [4] (Table 1).
Histologic analysis
All preclinical studies performed a histologic evalu-
ation of the FH’s after SC treatment, examining for
osteogenesis. In addition, 5 of the studies performed a
quantitative histomorphometric analysis for osteogenesis
[6,11,12,31,32]. Seven studies examined the FH’s for
neovascularization [6,11,17,30-32,34].
Imaging analysis
Six of the 11 studies used a variety of imaging techniques
to evaluate bone formation [6,10,11,30,32,34]. Wen et al.
used computed tomography (CT), magnetic resonance
imaging (MRI), and CT perfusion imaging to evaluate the
effectiveness of autologous cultured bone marrow SC
therapy [30]. Abudusaimi et al., Xie et al. and Aimaiti et al.
used micro CT scan to evaluate bone volume, bonemineral density and trabecular volume [10,32,34]. Sun
et al. used micro CT angiography to evaluate angiogenesis
[6]. Hang et al. used single photon emission computed
tomography (SPECT) and radiographs to evaluate bone
density and FH shape [11].
Preclinical study findings
Histology (11 studies)
Nine studies reported an increase in bone formation
in the SC treatment group compared to CD alone
[4,6,10-12,31-34] and two studies reported an increase
in bone formation compared to no treatment [17,30].
In the 5 studies that performed a quantitative histo-
morphometric analysis, all 5 studies reported signifi-
cantly increased bone formation (p < 0.05) following
SC therapy versus CD alone [6,11,12,31,32].
Five studies performing a histologic assessment of neo-
vascularization following SC treatment found improve-
ment (p < 0.05) in the SC treatment groups compared to
CD alone [6,11,30-32]. One study found higher levels of
Table 1 Preclinical study characteristics and results
Study Animal model Stem cell therapy Results
Histology Imaging
Bone formation Angiogenesis X-ray SPECT CT MR
Wen et al. [30] Rabbit BMMNC-MSC +ve +ve* – – +ve +ve
Sun et al. [6] Rabbit BMMNC +ve* +ve* – – +ve* –
Yan et al. [12] Dog BMMNC-MSC +ve* – – – – –
Feitosa et al. [4] Sheep hIDPSC, BMMNC-MSC +ve – – – – –
Abudusaimi et al. [10] Rabbit ADSC +ve – – – +ve* –
Aimaiti et al. [34] Rabbit ADSC +ve +ve – – +ve* –
Song et al. [17] Rabbit PBSC +ve +ve* – – – –
Sun et al. [31] Rabbit EPC +ve* +ve* – – – –
Hang et al. [11] Dog BMMNC-MSC +ve* +ve* +ve +ve – –
Wen et al. [33] Rabbit BMMNC-MSC +ve – – – – –
Xie et al. [32] Rabbit cBMMNC +ve* +ve* – – +ve* –
BMMNC-MSC = mesenchymal stem cells obtained post bone marrow mononuclear cell culture, hIDPSC = human immature dental pulp stem cells, ADSC =
adipose derived stem cells, PBSC = peripheral blood stem cells, EPC = endothelial progenitor cells, cBMMNC = cryoperserved bone marrow mononuclear cells,
+ve = positive effect compared to controls, −ve = negative effect compared to controls, – = not measured, * = statistically significant (p < 0.05).
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study did not perform statistical analysis but reported
higher levels of neovascularization [34] (Table 1).
Imaging (6 studies)
On CT imaging, Wen et al. found that the SC group had
imaging that closely resembled the normal hip in compari-
son to CD alone [30]. On MRI imaging they found de-
creased FH necrosis volume compared to no treatment,
and on CT perfusion imaging they found blood volume to
be similar to normal hips (no statistics reported) [30].
Abudusaimi et al., Xie et al. and Aimaiti et al. found sig-
nificantly higher bone volume, bone mineral density and
trabecular volume in the SC group compared to CD alone
(p < 0.05) on micro CT [10,32,34].
Sun et al. performed micro CT angiography and found
improved angiogenesis (p < 0.05) [6]. Hang et al. found
that the CD only group had decreased uptake of radio-
activity on SPECT compared to SC treatment group, indi-
cative of worse perfusion [11]. Radiographs also revealed
that the CD only group had worse results, with irregular
articular surfaces and heterogenous density of the FH in




The clinical studies included two randomized control
trials (RCT) [8,14], one non randomized comparison
study (nRCT) [2], and two case series [9,35]. The length
of follow up for the RCTs was 24 months [14], and
60 months [8]. The nRCT had a follow up of 60 months
[2]. The case series’ examined outcomes at an averagefollow up of 27.6 months (12–40 months) [9], and
13 years (8–18 years) [35].
Sample size
Sample size (n) was recorded as number of hips. Com-
bined, the 5 studies comprised 763 hips. Across studies,
n varied from a minimum of 24 [2] to a maximum of
534 [35] (Table 2). None of the studies reported a power
calculation.
Avascular necrosis classification and etiology
Combined, the studies included patients with the following
etiologies for AVN: trauma [8,14], steroid use [2,8,9,14,35],
ethanol use [2,8,9,14,35], pregnancy [14], Cushing’s disease
[14], Caisson disease [8], sickle cell disease [34], and idio-
pathic [2,8,9,14]. Hernigou et al. did not specify the cause
of AVN for 117 of 534 hips in their case series [35]
(Table 2). The severity of AVN was classified using two
grading systems across the 5 studies. Four of the studies
utilized the Association Research Circulation Osseous
(ARCO) classification [2,8,9,14] and included patients with
an ARCO classification of 1–2 (precollapse). One study
used the Ficat classification, and included patients in Ficat
stage 1 or 2 [35] (Table 2).
Stem cell treatment protocol
Four studies utilized concentrated BMMNC harvested
from the iliac crests of each patient as their SC treatment
[2,9,14,35]. Zhao et al. used cultured autologous BMMNC
harvested from the proximal femur of each patient as their
SC treatment [8]. After bone marrow was harvested,
in vitro expansion of the mesenchymal SC was performed
for 2 weeks prior to reimplantation. SC treatment was
Table 2 Clinical Study Characteristics
Study Type n Initial AVN class AVN etiology (# of hips) Treatment protocol
Hernigou et al. [35] Case series 534 Ficat 1-2 steroid (101), ethanol (150), sickle cell (166),
not specified (117)
Concentrated BMMNC
Wang et al. [9] Case series 50 ARCO 1-2 steroid (25), ethanol (19), idiopathic (6) Concentrated BMMNC
Gangji et al. [2] nRCT 24 ARCO 1-2 steroid (20), ethanol (2), idiopathic (2) Concentrated BMMNC
Sen et al. [14] RCT 51 ARCO 1-2 trauma (17), steroid (20), ethanol 8), idiopathic (2),
pregnancy (2), Cushings (2)
Concentrated BMMNC
Zhao et al. [8] RCT 97 ARCO 1C-2C trauma (20), steroid (24), ethanol (19), Caisson (11),
idiopathic (30) (some patients had more than one etiology)
Cultured BMMNC
BMMNC = bone marrow mononuclear cells, n = number of hips, ARCO = Association Research Circulation Osseous classification, nRCT = non randomized control
trial, RCT = randomized control trial.
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(Table 2).
Stem cell dose
SC dose was measured using a variety of methods - total
mononucleated cell count (TMNCC), CD34+ cell count,
number of fibroblast colony forming units (F-CFU) and
total mesenchymal SC count (TMSCC). TMNCC is a
measure of all the nucleated cells including mature nucle-
ated cells and mesenchymal SC. CD34+ cells are a marker
of hematopoeitic precursor cells and F-CFU are a measure
of mesenchymal SC (each F-CFU is thought to arise from
clonal expansion of mesenchymal SC). TMSCC is an
approximate count of the number of SC and was used
by Zhao et al. prior to reimplantation of cultured mes-
enchymal SC [8].
TMNCC was measured in 4 studies and ranged from
5 × 108 to 19 × 108 cells [2,9,14]. CD34+ cell counts
were measured in two studies (1.9 × 107 to 5 × 107 cells)
[2,14]. F-CFU counts were measured in two studies
(mean F-CFU count of 1.76 × 103 to 2.4 × 103) [2,35].
TMSCC was reported in one study (2.0 × 106 cells) [8]
(Table 3).
Examined outcomes
Across studies a variety of patient reported outcomes were
reported, including Harris Hip Score (HHS) (4 studies)
[8,9,14,35], Lequesne index (1 study) [2], Western Ontario
and McMaster Osteoarthritis index (WOMAC) (1 study)
[2], and pain visual analog score (VAS) (1 study) [2]. Three
studies examined progression to more advanced ARCOTable 3 Stem cell dose
Study TMNCC CD34
Hernigou et al. [35] –
Wang et al. [9] 15.5 × 108 cells
Gangji et al. [2] 19 × 108 cells 1.9
Sen et al. [14] 5 × 108 cells 5 ×
Zhao et al. [8] –
TMNCC = total mononucleated cell count, F-CFU = fibroblast colony forming units, Tstage [2,8,9], and 3 studies examined volume of necrotic
lesion by MRI [2,8,35]. Hip survivorship was measured
in all 5 studies and was defined as conversion to THA
(4 studies) [2,9,14,35], and conversion to THA or need
for vascularized bone grafting (1 study) [8]. Two studies
reported KM survival curves as part of their hip sur-
vivorship analysis [2,14].
Clinical study results
Patient reported outcomes (5 studies)
Four of the studies reported HHS [8,9,14,35]. Zhao et al.
found a statistically significant increase in HHS 60 months
following SC therapy compared to CD only in patients
with ARCO stage 1C/2B/2C (p < 0.05, raw score not re-
ported), and a trend for ARCO stage 2A (p = 0.06, raw
score not reported) [8]. Sen et al. found a statistically sig-
nificant difference in HHS for the SC treated patients
compared to CD only at 12 months follow up (83.65 ±
8.04 vs. 76.68 ± 13.86, p < 0.05) [14]. At 24 months, overall
HHS was not significantly improved between the two
groups (82.42 ± 9.63 vs. 77.39 ± 16.98, p = 0.09), but the
pain and deformity domains of the HHS were still in favor
of the SC therapy group (p < 0.05, raw score not reported)
[14]. Wang et al. reported statistically significant (p < 0.05)
improvements in HHS score at an average of 27.6 months
post SC treatment for patients in ARCO stage 1/2A/2B/
2C, from 90 ± 0.06 to 96 ± 0.06, 78.6 ± 1.02 to 92.5 ± 1.22,
68.2 ± 6.16 to 82.6 ± 8.23, and 67.8 ± 11.2 to 77.9 ± 15.15
respectively [9]. Hernigou et al. reported HHS on patients
that had not progressed to having THA (420 of 534 hips)
[35]. They reported HHS of 70 preoperatively and 88 post+ cell count F-CFU TMSCC
– 2.4 × 104 –
– – –
× 107 cells 1.76 × 104 –
107 cells – –
– – 2 × 106 cells
MSCC = total mesenchymal stem cell count.
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value reported) [35].
Gangji et al. examined 3 patient reported outcomes:
Lequesne index, VAS and WOMAC [2]. The SC treatment
group had improved Lequesne index compared to CD
group (SC group = 4.8 ± 1.8, CD group Lequesne index
not reported, p = 0.03), and improved VAS (SC group =
20.8 ± 7.7, CD group VAS not reported, p = 0.009).
WOMAC scores were not significantly different be-
tween the groups (raw scores not reported, p = 0.091)
[2] (Table 4).
Progression of avascular necrosis (3 studies)
Two of 3 studies found a significant decrease in the
proportion of patients progressing to ARCO stage 3 or
4 following SC treatment compared to CD only treat-
ment, 60 months post procedure (p < 0.05) [2,8]. Zhao
et al. reported a decrease from 22.7% (CD group) to
3.7% (SC group) [8] and Gangji et al. reported a de-
crease from 72.7% (CD group) to 23.1% (SC group) [2].
Gangji et al. also performed a KM survival analysis with
progression to ARCO stage 3 as the end point, and
found a significantly longer (p < 0.05) time to progres-
sion to ARCO stage 3 in the SC group compared to CDTable 4 Clinical study results for stem cell therapy




HHS (13 years) Improved compared to
baseline score (88 vs 70)^
Wang
et al. [9]
HHS Improved compared to
baseline score (83.7 ±
10.34 vs 71.2 ± 6.56)*




Lequesne index Improved compared to




VAS pain Improved compared to







HHS (12 months) Improved compared







CD (raw score NR)*
Decreased prog
(3.8% vs. 22.7%)*
HHS = Harris Hip Score, ARCO = Association Research Circulation Osseous classificati
McMaster Universities Osteoarthritis index, ^ = no statistics reported, * = p < 0.05, #
THA = total hip arthroplasty.[52.2 months (43.35 - 60.96, 95% confidence interval
(CI)) vs 26.5 months (13.2 - 39.74, 95% CI)] [2]. In their
case series, Wang et al. reported a 22% rate of progression
to higher ARCO stage (for hips in ARCO stage 1 or 2 be-
fore SC treatment) at an average follow up of 27 months
[9] (Table 4).
Volume of necrotic lesion (3 studies)
Zhao et al. reported a significant decrease in lesion volume
in SC treated hips compared to CD only treated hips with
a pretreatment ARCO stage of 2B and 2C (ARCO 2B =
6.5% vs 13.3% of FH, ARCO 2C = 13.8% vs 29.3% of FH,
p < 0.05) at 60 months post treatment [8]. Gangji et al.
reported a significant decrease in lesion volume after
SC treatment compared to CD only at 24 months follow
up (SC group volume decreased 42%, CD group volume
decreased 1%, p < 0.05), and a trend towards decreased
lesion volume at 60 months (SC group volume decreased
42%, CD group volume decreased 22%, p = 0.06) [2].
Hernigou et al. reported on lesion volume in 371 of 534
hips in their case series [35]. They found a decrease in
lesion size from 26 cm3 to 12 cm3 at an average of 12
years follow up (no statistical analysis reported) [35]
(Table 4).Lesion volume Hip survivorship
Decreased lesion volume
(12 cm3 vs 26 cm3)^
17.6% conversion rate to THA
at 13 years follow up
ogression
class




Decreased lesion volume at
24 months (SC group volume
decreased 42%, CD group
volume decreased 1%)*, no
improvement at 60 months
(SC group volume decreased
42%, CD group volume
decreased 22%)#
No improvement in hip
survivorship (57.2 months vs
50.2 months)
Improved hip survivorship
(51.85 ± 0.15 weeks vs.
46.62 ± 2.34 weeks)*
ression Decreased lesion volume
in ARCO 2B (6.5% vs 13.3%
of FH), and ARCO 2C (13.8%
vs 29.3%)*
Decreased rate of conversion
to THA/vascularized bone
graft in the SC group
compared to CD (3.7% vs.
22.7%)*
on, VAS = visual analog scale pain score, WOMAC =Western Ontario and
= p = 0.06, CD = core decompression, NR = not reported, FH = femoral head,
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Four studies examined conversion rate to THA [2,9,14,35].
Sen et al. performed KM hip survival analysis and they
found the SC treatment group to have significantly lon-
ger hip survival compared to CD alone [51.85 weeks
(51.54 - 52.15, 95% CI) vs 46.72 weeks (42.13 - 51.31,
95% CI), log rank test 4.44 p = 0.0351] [14]. Gangji et
al’s nRCT found no significant difference in rate of con-
version to THA between SC treatment and CD alone at
60 months of follow up (SC group: 14.3%, CD only
group: 27.3%, p > 0.05) [2]. They also performed a KM
survival analysis and found no significant difference in
time to THA between the two groups [mean time to
THA - SC group: 57.2 months (53.48–60.97 95% CI),
CD only group: 50.2 months (40.24–60.13 95% CI), log
rank test p = 0.42] [2]. Hernigou et al. found a 17.6%
conversion rate in their series over an average follow up
of 13 years [35], and Wang et al. found a conversion
rate of 12% over an average follow up of 27 months [9].
Zhao et al. found a significant decrease in rate of con-
version to THA or need for vascularized bone grafting
in the SC group compared to CD alone (3.7% vs. 22.7%,
p < 0.05) [8] (Table 4).
Discussion
This review systematically examined the current literature
on SC therapy for the treatment of early stage (precol-
lapse) AVN of the FH including clinical and preclinical
studies. Preclinical studies yielded encouraging results for
treatment of AVN of the FH with SC. Although the source
of SC varied among studies, SC treatment of AVN uni-
formly demonstrated improvements in osteogenesis and
vascularization. All 11 studies showed positive effects with
respect to bone formation in groups treated with SC. Fur-
thermore, reported X-ray, SPECT, CT and MR outcomes
from all studies favoured the SC treatment group. Bone
marrow was the most common source of SC but other
sources such as adipose and dental pulp were identified.
SC isolated from dental pulp represents a relatively new
treatment option with noteworthy potential for use in or-
thopaedics [4]. Adipose derived SC are another potential
alternative to SC from bone marrow. Advantages of adi-
pose derived SC include abundance, ease of isolation,
rapid expansion, and multipotency [10].
Despite positive results, relevance of animal models
described in preclinical studies should be considered.
Corticosteroid and liquid nitrogen induced AVN of the
FH are widely recognized means for induction of AVN
in numerous animal models; both lead to ischemic con-
ditions within the FM and eventual osseous infarction
producing changes phenotypically similar and clinically
relevant to human disease [36]. Some studies, however,
have addressed the significance of larger animal models,
particularly with respect to translational medicine, asthey may better replicate conditions in human AVN. An
ovine model of AVN of the FH may better reflect articu-
lation in early-stage human AVN as compared to other
disease models [4]. For liquid nitrogen induced disease,
the bone defect produced, which is non-negligible in ani-
mals with small diameter FHs, has been proposed as a
limitation due to its absence from human pathology. This
has led some researchers to reject use of this method on
rabbits [37].
Results of clinical studies were also encouraging. In
our review, the clinical studies used CD as a means for
implanting SC directly into the necrotic region of the
FH, in the form of a cell suspension. CD works by de-
creasing intra-osseous pressure and improving circula-
tion and vascularization [9]. Used alone, however, CD
exhibits inconsistent outcomes including poor lesion
reconstruction, ultimately leading to FH collapse [9,14].
The progression of AVN of the FH occurs in consequence
of a limited capacity for articular tissue self-repair
[3,11,14], including decreased osteogenesis [11,14] and
vascularization [3]. This may occur as a result of inad-
equate numbers of progenitor cells in the proximal
femur of patients with AVN of the FH [38]. It is thought
that SC implanted into the necrotic region of the FH
work to repopulate the low numbers of progenitor cells
[20]. Pluripotent, mesenchymal SC differentiate into
various cell types, namely osteoblasts, thereby improv-
ing repair mechanisms and potentially reversing damage
to bone [11,12,14]. In addition to directly increasing
bone formation by differentiating into osteoblasts, it is
hypothesized that mesenchymal SC have an indirect ef-
fect by the expression of cytokines which influence
osteogenesis and neovascularization [39,40]. In general,
clinical studies reported improvements in patient re-
ported outcomes for those treated with SC; notably, the
HHS. Similarly, studies that examined progression to
more advanced disease, and lesion volume reported im-
provements for the SC treatment group. Participants
treated with SC did not experience consistent improve-
ments in hip survivorship across studies. None of the
studies using a comparative group found worse outcomes
for SC treatment.
Considerable variations and inconsistent reporting
among clinical studies were observed regarding the dose
of SC, etiology of AVN, lesion size, and severity/classifi-
cation of disease making comparisons between studies
challenging. However, there are currently limited num-
bers of clinical studies addressing SC therapy for treat-
ment of AVN of the FH, and even fewer addressing
early-stage disease and administration of SC by CD. Ac-
cordingly, we were unable to perform meta-analysis on
study results. Quantitative assessment will be a prerequis-
ite to making definitive conclusions on vital therapy-
related factors such as SC dose and quality.
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a lack of uniformly accepted, reliable cell markers which
can be used to identify mesenchymal SC [39]. However,
the dose of SC used has been reported to impact disease
outcome [7]. Both SC dose and quality are also known
to affect their clinical potential. Density of SC trans-
planted to the necrotic FH was shown to affect the rate
of osteogenesis, and thereby bone repair [12]. Quality of
transplanted cells affects their proliferative capacity [41].
Prior to routine use of combined SC/CD therapy, de-
fined standards of SC dose and quality, such as CD34+
or CFU counts [42], will likely have to be set in order to
accurately evaluate the effect of each therapy. However,
as a result of presently observed inconsistencies, and a
paucity of studies in this area, further research, examining
both SC dose and quality will be prerequisite to routine
clinical use of this therapy.
Though not specifically addressed by studies assessed
in this review, the impact on treatment outcome of
whether cells were derived from a concentrate or a culture
may also represent an area for future research. Pre-clinical
and clinical studies included examples of both concen-
trated and cultured cells. Concentrated cells contain all
cells and cell types present in the tissue from which they
have been derived, not only SC. Concentrated BMMNC
from bone marrow aspirate contain hematopoietic pro-
genitor cells, lymphocytes, leucocytes, in addition to non-
hematopoietic cells including MSC, EPC, embryonic-like
SC expressing pluripotent markers, and other multipotent
or committed cells [43]. Cultured cells, conversely, repre-
sent an isolated pool of SC. The comparative regenerative
capacity of concentrated vs. cultured cells remains unclear.
Despite positive results observed for both treatments
within this review, other studies explicitly assessing differ-
ences between the two have displayed mixed findings. Use
of pure, cultured MSC led to greater improvements in
ischemic limb diseases, compared to concentrated
BMMNC, in both human and rat models [44,45]. Alter-
natively, BMMNC use displayed beneficial outcomes in
treatment of spinal cord injury when compared to MSC
[46]. Cost and feasibility must also be considered when
selecting an appropriate treatment. Indeed, cultured cells
require greater preparation times and are associated with
increased cost [44,47]. Ultimately, the outcomes of con-
centrated vs. cultured cells should be assessed for the
specific treatment of AVN of the FH in order to develop
future robust clinical guidelines for cellular intervention
in this disease.
Etiologic risk factors of AVN are also known to signifi-
cantly affect treatment outcomes [2]. It has been demon-
strated that the capacity for SC to differentiate into the
necessary osteogenic cells for bone repair and remodeling
is limited in patients with alcohol and steroid induced
AVN of the FH due to differences in the ischemicenvironment [12,48]. The size of the osteonecrotic le-
sion is also known to affect overall patient outcome no
matter the method of treatment used [8,49]. Future
studies should aim to use the same AVN classification
system as well as account for AVN etiology and lesion
size as potential confounding variables.
Several other reviews [18,38,50-53] have been published
discussing the use of SC for the treatment of AVN of the
femoral head. However to our knowledge, ours is the first
systematic review that includes data from several recently
published clinical trials [2,8,14]. Our review included data
from over 700 hips, more than previously published re-
views. Additionally, our review included both clinical and
pre-clinical studies, furthering the breadth of our review.
A limitation of any systematic review is in the quality of
the papers available for review. Clinical studies included in
our review did not provide sample size and power calcula-
tions. Preclinical studies did not always use a classification
system to identify stage of AVN of the FH. There were a
limited number of comparative trials, and only two RCTs.
We included all types of clinical studies, potentially intro-
ducing confounding and selection bias. We felt that inclu-
sion of these studies would provide a more comprehensive
review of the literature surrounding this topic. Further-
more, meta-analysis was not performed due to the limited
number of comparative trials and variable methodology
employed in the studies.
Conclusions
AVN of the FH primarily affects younger, working age
individuals and thus leads to increased morbidity and
functional disability in this population [13,30]. Treat-
ments aimed at halting or delaying progression of dis-
ease would provide a welcome alternative to those faced
with progression to joint collapse and hip replacement
surgery. Combining CD, the most widely used treatment
for AVN of the FH to date [30], with SC, could result in
a novel long lasting hip preserving treatment option.
Pre-clinical studies have demonstrated the potential of
SC for reversing the debilitating damage to the femoral
head associated with AVN in vitro. Current clinical
studies have suggested beneficial effects on patient re-
ported outcomes, but definitive conclusions regarding
hip survival and disease progression cannot be made.
Further, more refined clinical studies are needed to es-
tablish the effectiveness of SC treatment in AVN of the
FH. Quantitative studies including meta-analyses aimed
at addressing SC dose and quality standards will be ne-
cessary to make fundamental treatment-related deduc-
tions. The effects of concentration and culture based
preparatory methods for SC therapy should be compared
in the context of treating AVN of the FH in order to estab-
lish suitable protocols. Demonstrated improvement in hip
survivorship is prerequisite to the future of this treatment.
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